| AIS |
Adenocarcinoma in situ |
| ALTS |
ASCUS/LSIL Triage Study |
| AGC |
Atypical galndular cells |
| ASC |
Atypical squamous cells |
| ASC |
American Society of Cytology |
| ASCP |
American Society of Clinical Pathologists |
| ASC-H |
Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion |
| ASC-US |
Atypical squamous cells of undetermined significance |
| CAP |
College of American Pathologists |
| CIS |
Carcinoma in situ |
| CIN |
Cervical intraepithelial neoplasia |
| CP |
Conventional preparation |
| DES |
Diethylstilbestrol |
| HSIL |
High-grade squamous intraepitheial lesion |
| FIGO |
International Federation of Gynecology and Obstetrics |
| HPV |
Human Papilloma Virus |
| IARC |
International Agency for Research on Cancer |
| ISH |
In situ Hybridization |
| IUD |
Intrauterine device |
| LBP |
Liquid-based preparation |
| LEEP |
Loop electrosurgical |
| LMP |
Last menstrual period (in days) |
| LUS |
Lower uterine segment |
| LSIL |
Low-grade squamous intraepithelial lesion |
| N/C |
Nuclear/cytoplasmic ratio |
| NCI |
National Cancer Institute (Bethesda USA) |
| NILM |
Negative for intraepithelial lesion or malignancy |
| NOS |
Not otherwise specified |
| PCR |
Polymerase Chain Reaction |
| RB |
RetinoBlastoma (gene) |
| RCH |
Reserve cell hyperplasia |
| SCUC |
Small cell undifferentiated carcinoma |
| SCC |
Squamous cell carcinoma |
| SIL |
Squamous intraepithelial lesion |
| TBS |
The Bethesda System |
| TCC |
Transitional cell carcinoma (urothelial) |
| TNM |
Tumour Node Metastasis |
| T zone |
Transformation zone |
| UICC |
International Union Against Cancer |
| WHO |
World Health Organization |
Glossary Abbreviations